Newsroom
Sorted by: Latest
-
Lineaje Launches Continuous Vulnerability Elimination Factory, Powered by Frontier Defense™
SANTA CLARA, Calif.--(BUSINESS WIRE)--Lineaje, the pioneer in full-lifecycle autonomous software supply chain security, today announced its Continuous Vulnerability Elimination Factory (CVEF). Built to address the growing vulnerability challenges introduced by AI, CVEF continuously discovers, remediates, and eliminates exploitable vulnerabilities across proprietary code, open source, AI-generated code, and containers. CVEF also incorporates Frontier Defense™, an autonomous engine for detecting...
-
Law Offices of Frank R. Cruz Encourages GPGI, Inc. (GPGI) Shareholders To Inquire About Securities Fraud Class Action
LOS ANGELES--(BUSINESS WIRE)--Law Offices of Frank R. Cruz Encourages GPGI, Inc. (GPGI) Shareholders To Inquire About Securities Fraud Class Action...
-
Law Offices of Frank R. Cruz Encourages Planet Fitness, Inc. (PLNT) Shareholders To Inquire About Securities Fraud Class Action
LOS ANGELES--(BUSINESS WIRE)--Law Offices of Frank R. Cruz Encourages Planet Fitness, Inc. (PLNT) Shareholders To Inquire About Securities Fraud Class Action...
-
Sagepath Reply opgenomen in de Gartner® Market Guide for Strategic Website Agencies 2026
TURIJN, Italië--(BUSINESS WIRE)--Sagepath Reply, een bureau voor digitale ervaringen dat deel uitmaakt van de Reply Group, is opgenomen in de 2026 Gartner Market Guide for Strategic Website Agencies . Dit is de derde keer dat Sagepath Reply in de Market Guide wordt genoemd, na eerdere vermeldingen in 2023 en 2025. Gartner, een bedrijf dat bruikbare, objectieve inzichten levert aan leidinggevenden en hun teams, definieert strategische websitebureaus als "dienstverleners die zich toeleggen op het...
-
Citibank UK Regulatory Announcement: FRN Variable Rate Fix
LONDON--(BUSINESS WIRE)-- Re: OAK NO.5 PLC GBP 300,000,000.00 MATURING: 28-Jul-2072 ISIN: XS2985130645 PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD 28-Apr-2026 TO 28-Jul-2026 HAS BEEN FIXED AT 4.26 PCT DAY BASIS: ACTUAL/365(FIX) INTEREST PAYABLE VALUE 28-Jul-2026 WILL AMOUNT TO: GBP 3,228,643.96 PER GBP 304,200,424.63 DENOMINATION ...
-
Citibank UK Regulatory Announcement: FRN Variable Rate Fix
LONDON--(BUSINESS WIRE)-- Re: Equity Release Funding No 3 GBP 42,000,000.00 MATURING: 26-Apr-2038 ISIN: XS0169951000 PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD 27-Apr-2026 TO 27-Jul-2026 HAS BEEN FIXED AT 5.27 PCT DAY BASIS: ACTUAL/365(FIX) INTEREST PAYABLE VALUE 27-Jul-2026 WILL AMOUNT TO: GBP 18.37 PER GBP 1,000.00 DENOMINATION ...
-
Conti Federal Makes History with the US Army’s First OTA FORGE Contract
TACOMA, Wash.--(BUSINESS WIRE)--Conti Federal Services, LLC, a leading federal construction and design-build firm, has been awarded the first contract of its kind by the Mission and Installation Contracting Command (MICC) using the new Other Transaction Authority (OTA) for military facility construction and repair, securing a $169.1M firm-fixed price contract to execute the FORGE (Facilities, Operations, Readiness, Growth and Experience) Facilities Modernization Program at Joint Base Lewis-McCh...
-
Europäische Kommission genehmigt Crysvita® (burosumab) für Säuglinge mit X-chromosomaler Hypophosphatämie in der Europäischen Union
GALASHIELS, Schottland & MARLOW, England--(BUSINESS WIRE)--Kyowa Kirin EMEA, eine hundertprozentige Tochtergesellschaft der Kyowa Kirin Co., Ltd. (TSE:4151), gab heute bekannt, dass die Europäische Kommission (EK) eine Erweiterung der Indikation für Crysvita® (burosumab) zur Behandlung der X-chromosomalen Hypophosphatämie (XLH) auf Säuglinge im Alter von 1 Monat bis 1 Jahr in der gesamten Europäischen Union und im Europäischen Wirtschaftsraum genehmigt hat. Die Zulassung stellt einen wichtigen...
-
La Commission européenne approuve Crysvita® (burosumab) pour les nourrissons atteints d’hypophosphatémie liée au chromosome X dans l’Union européenne
GALASHIELS, Écosse et MARLOW, Angleterre--(BUSINESS WIRE)--Kyowa Kirin EMEA, filiale à 100 % de Kyowa Kirin Co., Ltd. (TSE : 4151), a annoncé aujourd’hui que la Commission européenne (CE) avait approuvé l’extension de l’indication de Crysvita® (burosumab) pour le traitement de l’hypophosphatémie liée au chromosome X (XLH), afin d’inclure les nourrissons âgés de 1 mois à 1 an dans l’ensemble de l’Union européenne et de l’Espace économique européen. Cette autorisation représente une avancée impor...
-
Tema Launches Healthcare AI ETF (HLTH)
NEW YORK--(BUSINESS WIRE)--Tema ETFs (“Tema”), a leader in institutional-quality and actively managed exchange-traded funds, today announced the launch of the Tema Healthcare AI ETF (HLTH). HLTH was developed to invest in one of AI’s largest and most consequential applications: improving healthcare. U.S. healthcare spending is forecast to approach $9 trillion by 2034, representing more than 20% of GDP.1 Yet healthcare accounted for just 8.9% of the S&P 500 as of June 30,2 leaving AI’s poten...